In Saudi Arabia, with over 32 million people and a growing healthcare industry, Admedus is now approved to sell their CardioCel biomaterial for heart valve repair surgeries and expand their Middle East presence. Admedus now sells CardioCel in many countries around the world and includes 135 medical centres, but Saudi Arabia is an important market for them since cardiovascular disease is the main cause of death in the country. They partnered with Genpharm for this expansion which is already active in Saudi Arabia and they are focusing on pediatric cardiac care first. The expansion is projected to keep Admedus on track for their anticipated $21 million revenue for the year. Wayne Paterson, CEO, told Proactive Investors, “This is the most significant approval for Admedus and our partners Genpharm in this key strategic region.”
Latest article
You better be-leaf it: Dawn Bio cultivates wood in a petri dish
In the Netherlands, a startup based at Wageningen University’s campus is pioneering technology to produce wood from cultured cells.
Dubbed Dawn Bio, the company has...
Algae-based snowboards from WNDR get nod from Time Magazine
In Utah, WNDR Alpine’s algae-based snowboards have been named to Time Magazine’s top 200 inventions list.
Unlike most snowboards, which are made out of petroleum-based...
Prince William’s Earthshot Prize names seaweed firm Coast 4C as a finalist
In Australia, a startup sustainably cultivating seaweed has been chosen as a finalist for Prince William’s 2024 Earthshot Prize.
Coast 4C works with farmers in...